Pharmaceutical Giants’ Patent Tactics Under Scrutiny Amid Concerns Over Diabetes and Weight Loss Drug Access

Recent findings suggest that two prominent pharmaceutical companies have been employing patent thickets to secure their positions as dominant forces in the market for GLP-1 diabetes and weight loss medications. The report indicates that these patent strategies potentially restrict drug access by maintaining monopolistic control over these critical medications, thus impacting patient availability and affordability. For further details, the original report can be accessed here.